Vyome Holdings, Inc. (NASDAQ:HIND – Get Free Report) was the target of a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 35,140 shares, a decline of 45.9% from the June 15th total of 64,989 shares. Based on an average daily volume of 20,610 shares, the short-interest ratio is presently 1.7 days. Approximately 0.7% of the company’s stock are short sold.
Vyome Price Performance
Vyome stock opened at $2.18 on Wednesday. Vyome has a fifty-two week low of $1.75 and a fifty-two week high of $18.60. The firm has a fifty day moving average price of $2.17 and a two-hundred day moving average price of $2.48. The firm has a market cap of $15.30 million, a price-to-earnings ratio of -0.18 and a beta of 1.49.
Vyome (NASDAQ:HIND – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million during the quarter. As a group, sell-side analysts expect that Vyome will post -0.6 earnings per share for the current year.
Wall Street Analyst Weigh In
Get Our Latest Report on Vyome
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Vyome stock. Millennium Management LLC acquired a new stake in shares of Vyome Holdings, Inc. (NASDAQ:HIND – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned about 0.80% of Vyome as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 22.06% of the company’s stock.
About Vyome
ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.
Further Reading
- Five stocks we like better than Vyome
- Blueprint for a Billion: Nebius Group Secures the AI Floor
- As the Iran War Resumes, 2 Energy ETFs Ride Oil’s Renewed Rally
- Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet
- Marriott vs. Viking: Why the Better Quarter Doesn’t Mean the Better Decade
Receive News & Ratings for Vyome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyome and related companies with MarketBeat.com's FREE daily email newsletter.
